Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 8-10 weeks | $ 297.00 | |
25 mg | 8-10 weeks | $ 987.00 | |
50 mg | 8-10 weeks | $ 1,360.00 | |
100 mg | 8-10 weeks | $ 1,860.00 |
Description | Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM). |
Targets&IC50 | CDK6-CyclinD1:2.92 nM (ki), CDK9-CyclinT2:0.626 nM (ki), CDK4-CyclinD1:3.96 nM (ki), CDK9-CyclinT1:1.68 nM (ki), CDK1-CyclinB:5.4 nM (ki), CDK1-CyclinA:9.1 nM (ki) |
In vitro | In both ABC and GCB subtypes, Voruciclib hydrochloride (0.5-5 μM; 6 hours) shows targeted downregulation of MCL-1 . Ki values for each target such as CDK9/cyc T2, CDK9/cyc T1, CDK6/cyc D1, CDK4/cyc D1, CDK1/cyc B, and CDK1/cyc A for Voruciclib hydrochloride are 0.626 nM, 1.68 nM, 2.92 nM, 3.96 nM, 5.4 nM, 9.1 nM, respectively. |
In vivo | Combination of Venetoclax (10 mpk, 1 mpk, 50 mpk, 25 mpk in U2932, RIVA, SU-DHL-4 and NU-DHL-1, respectively) and Voruciclib hydrochloride (200 mpk; Oral gavage) leads to enhance tumor growth inhibition compared to either drug alone in U2932, RIVA, SU-DHL-4 (six days per week for 4 weeks), and NU-DHL-1 models (five days per week for 3 weeks) of DLBCL. |
Molecular Weight | 506.3 |
Formula | C22H20Cl2F3NO5 |
CAS No. | 1000023-05-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (493.78 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Voruciclib hydrochloride 1000023-05-1 Cell Cycle/Checkpoint CDK Voruciclib Hydrochloride inhibitor inhibit